S

Synlogic

SYBX

1.68000
USD
-0.01
(-0.59%)
Market Closed
Volume
112
EPS
0
Div Yield
0
P/E
-0
Market Cap
17,310,241
Related Instruments
A
ACAD
-0.020
(-0.11%)
19.000 USD
A
AKBA
-0.10000
(-7.25%)
1.28000 USD
AMGN
2.78
(0.84%)
335.22 USD
A
ASLN
-0.09150
(-13.23%)
0.60000 USD
A
ATNX
-0.34000
(-19.65%)
1.43000 USD
B
BMRN
0.270
(0.32%)
84.620 USD
C
CRIS
-0.60000
(-11.05%)
4.83000 USD
C
CTMX
-0.04000
(-2.90%)
1.34000 USD
X
XLRN
0
(0%)
0.000000 USD
News

Title: Synlogic

Sector: Healthcare
Industry: Biotechnology
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformativetreatments for serious diseases.